NewAmsterdam Pharma Company N.V. (NAMS) — Financial statements
Income statement, balance sheet, and cash flow for NewAmsterdam Pharma Company N.V. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 23↓50.6% | 46↑223.4% | 14↓86.3% | 103 | 0.00 | |
| Cost of Revenue | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 22↓50.7% | 46↑223.4% | 14↓86.3% | 103 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 142↓6.3% | 151↓5.0% | 159↑83.8% | 87↑199.4% | 29 | |
| General & Administrative Expenses | 106↑50.9% | 70↑87.2% | 38↑92.9% | 20↑315.0% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.98 | |
| SG&A Expenses | 106↑50.9% | 70↑87.2% | 38↑92.9% | 20↑243.6% | 6 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.33 | |
| Operating Expenses | 248↑11.8% | 222↑12.6% | 197↑85.5% | 106↑203.8% | 35 | |
| Total Costs & Expenses | 248↑11.9% | 222↑12.6% | 197↑85.5% | 106↑203.8% | 35 | |
| Operating Results | ||||||
| Operating Income | -226↓28.0% | -176↑3.6% | -183↓5043.9% | -4↑89.8% | -35 | |
| Depreciation & Amortization | 0.22↑94.7% | 0.11↑130.6% | 0.05↑444.4% | 0.01↑80.0% | 0.01 | |
| EBITDA | -242↓0.3% | -241↓36.5% | -177↓691.7% | -22↑46.0% | -41 | |
| EBIT | -243↓0.4% | -242↓36.6% | -177↓691.6% | -22↑46.0% | -41 | |
| Interest & Other Income | ||||||
| Net Interest Income | 28↑63.5% | 17↑393.5% | 3↑1292.0% | -0.29↑30.2% | -0.41 | |
| Interest Income | 28↑63.5% | 17↑65.2% | 10 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 7↑2269.0% | 0.29↓30.2% | 0.41 | |
| Non-Operating Income | 17↓74.2% | 65↑1178.3% | -6↓132.2% | 19↑193.7% | 6 | |
| Other Income / Expenses | 22↑133.5% | -65↓1178.3% | 6↑131.8% | -19↓180.2% | -7 | |
| Income Before Tax | -204↑15.6% | -242↓36.6% | -177↓681.6% | -23↑45.8% | -42 | |
| Income Tax Expense | 0.00↑100.0% | -0.00↓103.7% | 0.03 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -204↑15.6% | -242↓36.5% | -177↓681.7% | -23↑45.8% | -42 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -204↑15.6% | -242↓36.5% | -177↓681.7% | -23↑45.8% | -42 | |
| Bottom-Line Net Income | -204↑15.6% | -242↓36.5% | -177↓681.7% | -23↑45.8% | -42 | |
| EPS (Basic) | -1.75↑31.6% | -2.56↓19.1% | -2.15↓80.7% | -1.19↑64.4% | -3.34 | |
| EPS (Diluted) | -1.75↑31.6% | -2.56↓19.1% | -2.15↓80.7% | -1.19↑64.4% | -3.34 | |
| Weighted Average Shares | 114↑21.2% | 94↑14.8% | 82↑333.2% | 19↑6.8% | 18 | |
| Weighted Average Diluted Shares | 114↑21.2% | 94↑14.8% | 82↑333.2% | 19↑6.8% | 18 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.